Oracle Life Sciences Vice President of Global Innovation, Kathy Vandebelt, interviews industry experts and leaders on pressing topics in the Life Sciences industry.
Artificially intelligent tools are revolutionizing nearly
every stage of the drug discovery process, offering substantial
potential to reshape the speed and economics of the industry. As
the drug discovery and preclinical stages speed up and potentially
produce more drugs to test in the clinical trial phase,
how...
Artificial intelligence (AI) is one of the most discussed
technologies across all industries. Life science professionals
working in the pharmaceutical industry strive to improve people’s
lives tackling incredibly complex diseases. Drug development is
often perceived as slow. As the pharma industry looks to improve
the...
Cancer is a leading cause of death worldwide, accounting for
nearly 10 million deaths in 2020. President Biden has reignited the
Cancer Moonshot initiative and set a new national goal: “if we work
together, we can cut the death rate from cancer by at least 50%
over the next 25 years and improve the experience of...
The US cancer death rate has fallen by 33% since 1991 with an
estimated 3.8 million deaths averted. This is attributed to “good
progress” improvements in cancer treatment, decreases in smoking,
and increases in early detection. A recent rise in advanced cancer
cases reported is believed to be an outcome of the...
The success or failure of clinical trials is dependent in
large part on the engagement of the principal investigator (PI).
PIs play an important role in trial selection, site activation, and
study execution. This includes but is not limited to, the
development and implementation of a strategy to maximize
enrollment,...
Oracle Life Sciences Vice President of Global Innovation, Kathy Vandebelt, interviews industry experts and leaders on pressing topics in the Life Sciences industry.